218 related articles for article (PubMed ID: 24126229)
1. Pasireotide and mifepristone: new options in the medical management of Cushing's disease.
Cohan P
Endocr Pract; 2014 Jan; 20(1):84-93. PubMed ID: 24126229
[TBL] [Abstract][Full Text] [Related]
2. Pasireotide: a review of its use in Cushing's disease.
McKeage K
Drugs; 2013 May; 73(6):563-74. PubMed ID: 23605695
[TBL] [Abstract][Full Text] [Related]
3. Cushing's disease: current medical therapies and molecular insights guiding future therapies.
Lau D; Rutledge C; Aghi MK
Neurosurg Focus; 2015 Feb; 38(2):E11. PubMed ID: 25639313
[TBL] [Abstract][Full Text] [Related]
4. Medical management of Cushing's disease: what is the future?
Fleseriu M; Petersenn S
Pituitary; 2012 Sep; 15(3):330-41. PubMed ID: 22674211
[TBL] [Abstract][Full Text] [Related]
5. The Treatment of Cushing's Disease.
Pivonello R; De Leo M; Cozzolino A; Colao A
Endocr Rev; 2015 Aug; 36(4):385-486. PubMed ID: 26067718
[TBL] [Abstract][Full Text] [Related]
6. Medical treatment of Cushing's disease: somatostatin analogues and pasireotide.
Pedroncelli AM
Neuroendocrinology; 2010; 92 Suppl 1():120-4. PubMed ID: 20829632
[TBL] [Abstract][Full Text] [Related]
7. Managing hyperglycemia in patients with Cushing's disease treated with pasireotide: medical expert recommendations.
Colao A; De Block C; Gaztambide MS; Kumar S; Seufert J; Casanueva FF
Pituitary; 2014 Apr; 17(2):180-6. PubMed ID: 23564338
[TBL] [Abstract][Full Text] [Related]
8. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.
Boscaro M; Ludlam WH; Atkinson B; Glusman JE; Petersenn S; Reincke M; Snyder P; Tabarin A; Biller BM; Findling J; Melmed S; Darby CH; Hu K; Wang Y; Freda PU; Grossman AB; Frohman LA; Bertherat J
J Clin Endocrinol Metab; 2009 Jan; 94(1):115-22. PubMed ID: 18957506
[TBL] [Abstract][Full Text] [Related]
9. New avenues in the medical treatment of Cushing's disease: corticotroph tumor targeted therapy.
Fleseriu M; Petersenn S
J Neurooncol; 2013 Aug; 114(1):1-11. PubMed ID: 23673515
[TBL] [Abstract][Full Text] [Related]
10. Mifepristone: is there a place in the treatment of Cushing's disease?
Carmichael JD; Fleseriu M
Endocrine; 2013 Aug; 44(1):20-32. PubMed ID: 23192246
[TBL] [Abstract][Full Text] [Related]
11. Long-term medical treatment of cushing's disease with pasireotide: a review of current evidence and clinical experience.
Samson SL
Exp Clin Endocrinol Diabetes; 2014 Sep; 122(8):445-50. PubMed ID: 25003365
[TBL] [Abstract][Full Text] [Related]
12. A 12-month phase 3 study of pasireotide in Cushing's disease.
Colao A; Petersenn S; Newell-Price J; Findling JW; Gu F; Maldonado M; Schoenherr U; Mills D; Salgado LR; Biller BM;
N Engl J Med; 2012 Mar; 366(10):914-24. PubMed ID: 22397653
[TBL] [Abstract][Full Text] [Related]
13. A Single-Center 10-Year Experience with Pasireotide in Cushing's Disease: Patients' Characteristics and Outcome.
Trementino L; Michetti G; Angeletti A; Marcelli G; Concettoni C; Cardinaletti C; Polenta B; Boscaro M; Arnaldi G
Horm Metab Res; 2016 May; 48(5):290-8. PubMed ID: 27127913
[TBL] [Abstract][Full Text] [Related]
14. Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators.
Mallick S; Chakrabarti J; Eschbacher J; Moraitis AG; Greenstein AE; Churko J; Pond KW; Livolsi A; Thorne CA; Little AS; Yuen KCJ; Zavros Y
Transl Res; 2023 Jun; 256():56-72. PubMed ID: 36640905
[TBL] [Abstract][Full Text] [Related]
15. Clinical management of critically ill patients with Cushing's disease due to ACTH-secreting pituitary macroadenomas: effectiveness of presurgical treatment with pasireotide.
Cannavo S; Messina E; Albani A; Ferrau F; Barresi V; Priola S; Esposito F; Angileri F
Endocrine; 2016 Jun; 52(3):481-7. PubMed ID: 25877016
[TBL] [Abstract][Full Text] [Related]
16. Drugs in the medical treatment of Cushing's syndrome--an update on mifepristone and pasireotide.
Schteingart DE
Expert Opin Emerg Drugs; 2012 Sep; 17(3):279-83. PubMed ID: 22533823
[No Abstract] [Full Text] [Related]
17. Budget impact of pasireotide for the treatment of Cushing's disease, a rare endocrine disorder associated with considerable comorbidities.
Truong HL; Nellesen D; Ludlam WH; Neary MP
J Med Econ; 2014 Apr; 17(4):288-95. PubMed ID: 24617917
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial.
Petersenn S; Salgado LR; Schopohl J; Portocarrero-Ortiz L; Arnaldi G; Lacroix A; Scaroni C; Ravichandran S; Kandra A; Biller BMK
Endocrine; 2017 Jul; 57(1):156-165. PubMed ID: 28597198
[TBL] [Abstract][Full Text] [Related]
19. Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review.
Shimon I; Rot L; Inbar E
Pituitary; 2012 Dec; 15(4):608-13. PubMed ID: 22918543
[TBL] [Abstract][Full Text] [Related]
20. Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegaly.
Silverstein JM
Pituitary; 2016 Oct; 19(5):536-43. PubMed ID: 27405306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
